TIXiMED
Agent50Agent Readiness: 50/100. Top 25%. Measured by StartupHub.ai. Median 41.Clinical-stage pharmaceutical company developing innovative oral therapies for diabetes and metabolic disorders.
About
TIXiMED is developing TIX100, a first-of-its-kind oral therapeutic that inhibits TXNIP, as a treatment for Type 1 and Type 2 Diabetes, as well as metabolic dysfunction, associated steatotic liver disease (MASLD). The company has successfully completed a Phase 1 clinical study of TIX100 in human subjects. TIX100 is an orally administered novel chemical entity that has shown efficacy in preclinical models and aims to address the underlying causes of diabetes without causing hypoglycemia or weight gain.
Key facts
At-a-glance profile data
- Website
- tiximed.com
- Headquarters
- Birmingham, Alabama, United States
- Founded
- 2021
- Employees
- 5
- Total funding
- $5M (Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 13 Mar 2026 | Seed | $2M | Helmsley Charitable Trust |
| 19 Dec 2024 | Seed | $3M | Helmsley Charitable Trust |
Tech stack
Detected on tiximed.com, last scanned 18 Oct 2026. Run your own scan
- Hosting
- Google Cloud
- Email provider
- Google Workspace
Frequently asked
How much funding has TIXiMED raised?
TIXiMED has raised a total of $5M in funding. The most recent round on record is Seed.
How many employees does TIXiMED have?
TIXiMED has approximately 5 people on record.